Stockreport

Pulse Biosciences Announces Positive 60-Day Follow-Up Evaluations for Initial Patients treated in the CellFX® nsPFA™ 360° Cardiac Catheter First-in-Human Feasibility Study [Yahoo! Finance]

Pulse Biosciences, Inc  (PLSE) 
Last pulse biosciences, inc earnings: 11/7 03:42 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.pulsebiosciences.com
PDF and proprietary CellFX Nanosecond Pulsed Field Ablation (nsPFA) technology for the treatment of atrial fibrillation, today announced favorable findings from the 60-day p [Read more]